Vaxart to Present at the World Vaccine Congress Washington 2021
Dr. Tucker’s presentation titled, “
Presentation details are as follows:
Title:
Track: COVID-19: vaccine response & approaches
Time:
The World Vaccine Congress is the largest, most established meeting dedicated to vaccines. From basic research to commercial manufacture, this one meeting covers the whole vaccine value chain where science, government and manufacturers all come together to create groundbreaking progress.
To register for the virtual conference, which this year is free to attend, please click here.
About
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include vaccines in tablet form designed to protect against coronavirus, Norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contacts Media Relations |
Investor Relations |
Gloria Gasaatura 646 970 4688 ggasaatura@lifescicomms.com |
646 970 4995 dholmes@lifesciadvisors.com |
Source: Vaxart, Inc.